ArticleCancer cell2016
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.
Abstract read
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 298 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed, 4 pooled it
33.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
298 citing papers in PubMed, 4 syntheses or guidelines pooled it, 564 citations in OpenAlex.
- Pediatrics supratentorial intraventricular atypical teratoid/rhabdoid tumors: a case report and a systematic review of the literature.European journal of pediatrics · 2026Pooled it
- Whole-genome sequencing analysis of an atypical teratoid/rhabdoid tumor in a patient with Phelan-McDermid syndrome: a case report and systematic review.Brain tumor pathology · 2022Pooled it
- Atypical teratoid/rhabdoid tumor in adults: a systematic review of the literature with meta-analysis and additional reports of 4 cases.Journal of neuro-oncology · 2022Pooled it
- Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.Neuro-oncology · 2020Pooled it
- Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.Acta neuropathologica · 2020Trial
- A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.Cancer medicine · 2026Article
- HMGA proteins in the nervous system: role in brain tumorigenesis and neurodegeneration.Cell death discovery · 2026Review
- Proposal of a Risk Stratification Algorithm for Extracranial Malignant Rhabdoid Tumors.Cancer medicine · 2026Article
- Molecular changes during AT/RT progression associated with epithelial-mesenchymal transition and extracellular matrix changes.Acta neuropathologica · 2026Article
- Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenografts.Drug delivery and translational research · 2026Article
- Epigenetic collapse establishes transcriptional bottlenecks in malignant rhabdoid tumor.Clinical epigenetics · 2026Review
- Clinicopathological Characterization of Pediatric Atypical Teratoid/Rhabdoid Tumors and an HE-IHC Dual-Path Deep Learning Model for Auxiliary Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- Atypical Teratoid/Rhabdoid Tumor of the Lateral Ventricle: A Case Series and Experience with Molecular Subtyping-Guided Immunotherapy.Neurology international · 2026Article
- Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options.Cancers · 2026Review
- Aggressive atypical teratoid/rhabdoid tumor with extensive leptomeningeal metastasis in an 8-year-old boy: a case report and narrative review.Translational pediatrics · 2026Article
- Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy.Molecular therapy. Oncology · 2026Article
- Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Frontiers in oncology · 2026Review
- Germline Predisposition in Pediatric Central Nervous System Tumors: Insights from a Multigene Panel Study.Oncology research · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
58 authors at 20 institutions in 8 countries.
Pascal D JohannDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Serap ErkekDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; European Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg, Germany.
Marc ZapatkaGerman Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany.
Kornelius KerlDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, 48149 Münster, Germany.
Ivo BuchhalterDivision of Theoretical Bioinformatics, German Cancer Research Center, 69120 Heidelberg, Germany.
Volker HovestadtGerman Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany.
David T W JonesDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany.
Dominik SturmDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Carl HermannDivision of Theoretical Bioinformatics, German Cancer Research Center, 69120 Heidelberg, Germany.
Maia Segura WangEuropean Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg, Germany.
Andrey KorshunovDepartment of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, 69120 Heidelberg, Germany.
Marina RhyzovaDepartment of Neuropathology, Burdenko Neurosurgical Institute, 125047 Moscow, Russia.
Susanne GröbnerDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
Sebastian BrabetzDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
Lukas ChavezDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
Susanne BensInstitute for Human Genetics, 24105 Kiel, Germany.
Stefan GröschelDivision of Translational Oncology, Nationales Centrum für Tumorerkrankungen NCT, 69120 Heidelberg, Germany.
Fabian KratochwilDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany.
Andrea WittmannDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany.
Laura SieberDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany.
Christina GeörgDivision of Translational Oncology, Nationales Centrum für Tumorerkrankungen NCT, 69120 Heidelberg, Germany.
Stefan WolfGenomics and Proteomics Core Facility, German Cancer Research Center, 69120 Heidelberg, Germany.
Katja BeckGerman Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany.
Florian OyenDepartment of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
David CapperDepartment of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, 69120 Heidelberg, Germany.
Peter van SluisDepartment of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
Richard VolckmannDepartment of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
Rogier VersteegDepartment of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
Andreas von DeimlingDepartment of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, 69120 Heidelberg, Germany.
Till MildeDepartment of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Olaf WittDepartment of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Andreas E KulozikDepartment of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Martin EbingerDepartment of General Pediatrics, Hematology and Oncology, University of Tübingen, 72076 Tübingen, Germany.
Tarek ShalabyDepartment of Neuro-Oncology, Children's Research Center, University Children's Hospital, 8032 Zürich, Switzerland.
Michael GrotzerDepartment of Neuro-Oncology, Children's Research Center, University Children's Hospital, 8032 Zürich, Switzerland.
David SumerauerDepartment of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, 15006 Prague, Czech Republic.
Josef ZamecnikDeptartment of Pathology and Molecular Medicine, Charles University, 2nd Medical Faculty, University Hospital Motol, 15006 Prague, Czech Republic.
Jaume MoraDepartment of Hematology and Oncology, Children's Hospital, Hospital San Joan de Deu, 08950 Barcelona, Spain.
Nada JabadoDepartments of Pediatrics and Human Genetics, McGill University Health Center Research Institute, Montreal, QC H3A 1A4, Canada.
Michael D TaylorArthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, University of Toronto, Toronto, ON M5G0A4, Canada.
Annie HuangArthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, University of Toronto, Toronto, ON M5G0A4, Canada.
Eleonora AronicaDepartment of Neuropathology, Academic Medical Center, 20246 Amsterdam, the Netherlands.
Anna BertoniDivision of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany.
Bernhard RadlwimmerDivision of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany.
Torsten PietschDepartment of Neuropathology, University of Bonn, 53127 Bonn, Germany.
Ulrich SchüllerCenter of Neuropathology, Ludwig-Maximilians-Universität, 81377 Munich, Germany.
Reinhard SchneppenheimDepartment of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
Paul A NorthcottDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany.
Jan O KorbelEuropean Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg, Germany.
Reiner SiebertInstitute for Human Genetics, 24105 Kiel, Germany.
Michael C FrühwaldSwabian Childrens' Cancer Center, Children's Hospital Augsburg, 86156 Augsburg, Germany; EU-RHAB registry Center, 86156 Augsburg, Germany.
Peter LichterGerman Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany; Heidelberg Center for Personalized Oncology, DKFZ-HIPO, DKFZ, 69120 Heidelberg, Germany.
Roland EilsDivision of Theoretical Bioinformatics, German Cancer Research Center, 69120 Heidelberg, Germany; Heidelberg Center for Personalized Oncology, DKFZ-HIPO, DKFZ, 69120 Heidelberg, Germany.
Amar GajjarSt Jude Children's Research Hospital, Memphis, TN 38105, USA.
Martin HasselblattInstitute of Neuropathology, University Hospital Münster, 48149 Münster, Germany.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Marcel KoolDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany. Electronic address: m.kool@dkfz.de.
Heidelberg University · DEGerman Cancer Research Center · DEUniversity Hospital Heidelberg · DEAmsterdam UMC Location University of Amsterdam · NLDeutschen Konsortium für Translationale Krebsforschung · DECharles University · CZEuropean Molecular Biology Laboratory · DENational Center for Tumor Diseases · DEUniversity Children's Hospital Zurich · CHUniversity Hospital Münster · DEUniversity of Toronto · CABurdenko Neurosurgery Institute · RUHopp Children's Cancer Center Heidelberg · DEHospital Sant Joan de Déu Barcelona · ESLudwig-Maximilians-Universität München · DEMcGill University Health Centre · CASt. Jude Children's Research Hospital · USUniversität Hamburg · DEUniversity Hospital Augsburg · DEUniversity Medical Center Hamburg-Eppendorf · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants. Although the prognosis of ATRT patients is poor, some patients respond favorably to current treatments, suggesting molecular inter-tumor heterogeneity. To investigate this further, we genetically and epigenetically analyzed 192 ATRTs. Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location, and type of SMARCB1 alterations, were identified. Whole-genome DNA and RNA sequencing found no recurrent mutations in addition to SMARCB1 that would explain the differences between subgroups. Whole-genome bisulfite sequencing and H3K27Ac chromatin-immunoprecipitation sequencing of primary tumors, however, revealed clear differences, leading to the identification of subgroup-specific regulatory networks and potential therapeutic targets.
Indexed as
Brain NeoplasmsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsEpigenesis, GeneticHumansMutationRhabdoid TumorSMARCB1 ProteinTeratomaTranscription FactorsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsSMARCB1 ProteinSMARCB1 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.